iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: http://www.ncbi.nlm.nih.gov/pubmed/34638275
Pertuzumab and Trastuzumab Combination with Concomitant Locoregional Radiotherapy for the Treatment of Breast Cancers with HER2 Receptor Overexpression - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 24;13(19):4790.
doi: 10.3390/cancers13194790.

Pertuzumab and Trastuzumab Combination with Concomitant Locoregional Radiotherapy for the Treatment of Breast Cancers with HER2 Receptor Overexpression

Amélie Aboudaram  1 , Pierre Loap  1 , Delphine Loirat  2 , Syrine Ben Dhia  1 , Kim Cao  1 , Alain Fourquet  1 , Youlia Kirova  1
Affiliations

Pertuzumab and Trastuzumab Combination with Concomitant Locoregional Radiotherapy for the Treatment of Breast Cancers with HER2 Receptor Overexpression

Amélie Aboudaram et al. Cancers (Basel). .

Abstract

Background: The combination of pertuzumab and trastuzumab dual HER2 blockade with concomitant curative dose locoregional breast radiotherapy in patients with metastatic breast cancer is an important part of treatment strategy.

Methods: This was a retrospective study conducted at the Institut Curie on all patients treated concomitantly with pertuzumab/trastuzumab and locoregional breast radiotherapy. Toxicity was evaluated according to the NCICTCAEv4.0. Overall survival, progression-free survival and locoregional recurrence-free survival were evaluated in metastatic patients who were initially well controlled by chemotherapy, for whom local treatment was decided by the multidisciplinary team.

Results: Fifty-five patients treated between October 2013 and December 2019 were included, with a median follow-up of 4.1 years. The median age was 53 years (range: 28-81). All patients received curative dose radiotherapy (RT) concomitantly with pertuzumab and trastuzumab (Pertu/Trastu). The median radiation dose was 50 Gy. Safety evaluation did not reveal any significant adverse effects, with 3 cases of grade 3 radiodermatitis (5.4%), but no significant gastrointestinal or cardiac toxicity. The mean difference in LVEF before any chemotherapy and after radiotherapy was -2.43% (p < 0.01).

Conclusions: This study demonstrates that the combination of locoregional breast RT with dual HER2 blockade by Pertu/Trastu was very well tolerated, suggesting that RT can be safely administered to patients with HER2-positive breast cancer.

Keywords: breast cancer; concurrent pertuzumab-trastuzumab-radiotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flowchart.
Figure 2
Figure 2
Overall survival of the population with metastatic disease at the time of diagnosis after concomitant RT and Pertu/Trastu dual HER2 blockade. Confidence intervals are provided in grey.
Figure 3
Figure 3
Progression-free survival of the population with metastatic disease at the time of diagnosis after concomitant RT and Pertu/Trastu dual HER2 blockade. Confidence intervals are provided in grey.
Figure 4
Figure 4
Locoregional recurrence-free survival in the population with metastatic disease at the time of diagnosis after concomitant RT and Pertu/Trastu dual HER2 blockade. Confidence intervals are provided in grey.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kümler I., Tuxen M.K., Nielsen D.L. A systematic review of dual targeting in HER2-positive breast cancer. Cancer Treat. Rev. 2014;40:259–270. doi: 10.1016/j.ctrv.2013.09.002. - DOI - PubMed
    1. Olayioye M.A., Neve R.M., Lane H.A., Hynes N.E. The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J. 2000;19:3159–3167. doi: 10.1093/emboj/19.13.3159. - DOI - PMC - PubMed
    1. Hudziak R.M., Lewis G.D., Winget M., Fendly B.M., Shepard H.M., Ullrich A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell Biol. 1989;9:1165–1172. doi: 10.1128/MCB.9.3.1165. - DOI - PMC - PubMed
    1. Barok M., Isola J., Pályi-Krekk Z., Nagy P., Juhász I., Vereb G., Kauraniemi P., Kapanen A., Tanner M., Szöllösi J. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol. Cancer Ther. 2007;6:2065–2072. doi: 10.1158/1535-7163.MCT-06-0766. - DOI - PubMed
    1. Moja L., Tagliabue L., Balduzzi S., Parmelli E., Pistotti V., Guarneri V., D’Amico R. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst. Rev. 2012;2012:CD006243. doi: 10.1002/14651858.CD006243.pub2. - DOI - PMC - PubMed